• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    D

    Doylestown Hospital

    EST. 1923
    99论文总数
    4,570引用总数

    论文量&引用量时间轴

    机构学者

    论文(99)

    年份
    起
    –
    止
    排序
    1Sedation Strategies in Pulsed Field Ablation: US Experience from the VOLT-AF IDE Trial
    Alok Gambhir, Monica Lo,Stavros Mountantonakis,Christopher Woods,Sri Sundaram,David DeLurgio, Amar Trivedi,David Strouse, Brett Atwater, Usman Siddiqui,Hugh Calkins,Bradley Knight,
    2026JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    2Multicenter Study on the Safety of Pulsed Field Ablation in over 40,000 Patients: MANIFEST-US
    Mohit K Turagam,Arash Aryana, John D Day,Srinivas R Dukkipati, Troy Hounshell, Devi Nair,Andrea Natale,Stanislav Weiner,Jim W Cheung, Larry Chinitz,Frank Cuoco,Marcos Daccarett,

    BACKGROUND:Pulsed field ablation (PFA) is emerging as the preferred energy source for atrial fibrillation ablation, largely because of its promising safety profile, including lower risks of esophageal injury, pulmonary vein stenosis, and phrenic nerve injury. However, rare complications may only emerge after treating many thousands of patients. OBJECTIVES:This study sought to determine the real-world utilization and safety profile of the pentaspline PFA catheter in the United States. METHODS:In this retrospective analysis, invitations were sent to U.S. centers performing PFA with the pentaspline catheter. Centers submitted data on patient demographics, procedural details, and adverse events (AEs). The main outcomes included the incidence of major and minor procedure-related AEs. RESULTS:Of the 435 centers contacted, 102 participated, averaging 5.1 operators per center (range 1-16 operators per center). Each center treated a median of 412 patients (range 26-1,961 patients), totaling 41,968 patients between February 2024 and July 2025. The median patient age was 68 years (range 17-99 years), and 56% were male. Most patients underwent first-time ablation (73%), primarily for paroxysmal (54%) or persistent atrial fibrillation (37%). Pulmonary vein isolation was performed in 93% of patients, with extravenous lesions on the posterior wall (57%), cavotricuspid isthmus (31%), or mitral isthmus (14%). Major AEs occurred in only 0.63% of patients, including cardiac tamponade (0.16%), vascular injury requiring intervention (0.18%), and stroke (0.10%). Importantly, no cases of esophageal fistula, persistent phrenic nerve paralysis, or pulmonary vein stenosis occurred. Mortality at 30 days was rare (0.04%), but there was a potential signal for rare (0.019%) unexplained sudden death/cardiac arrest. Rare AEs included coronary spasm (0.10%) and acute renal failure requiring dialysis (0.02%). Minor complications were reported in 2.05%, mainly vascular issues (0.96%), pericarditis (0.52%), and self-limited esophageal dysmotility (0.04%). CONCLUSIONS:In a real-world setting of unselected U.S. patients, PFA demonstrated a safety profile consistent with preferentiality to functional myocardial tissue ablation, without evidence of esophageal fistula or pulmonary vein stenosis. The major complication rate was ∼0.6%-mostly vascular AEs and pericardial tamponade. Stroke (∼1 in 1,000) and death (∼1 in 2,000) were rare. These data indicate that the initial implementation of pentaspline PFA has been overall safe.

    2025Journal of the American College of Cardiology(2025)引用:13
    引用
    AI阅读
    加入学术空间
    31696-P: ENT-03 Has Additive Weight Loss and Insulin Normalization Effects with Semaglutide in Diet-Induced Obesity (DIO) in Mice
    WILLIAM A. KINNEY,MICHAEL B. ZEMEL,G. ALEXANDER FLEMING,ALAN C. MOSES, RICHARD S. LARSON

    Introduction and Objective: Obesity and T2D remain major health concerns worldwide. We have recently described a centrally acting aminosterol, ENT-03, that induces weight loss in obese and lean rodents. ENT-03 is a synthetic version of the mammalian natural product, which is in Phase 1 clinical trials for treatment of type 2 diabetes and obesity. In this study, we examine metabolic effects of ENT-03 alone and in combination with Semaglutide (SG). Methods: To compare the effects of ENT-03 or SG on DIO mice, animals were treated for 10 wks with eithersubcutaneous administration of SG (daily at 0.04 mg/kg), ENT-03 (twice weekly at 25mg/kg) or vehicle control. Mice remained on a high fat diet and followed for an additional 10 wks after treatment discontinuation. Body weight, glucose, insulin, and metabolic cage data were monitored. Results: ENT-03 produced greater weight (31% vs. 20%, p= 0.003) and fat (53% vs. 35%, P=0.01) loss over 10 weeks of treatment vs. SG, but the combination of ENT-03 and SG produced a somewhat greater effect on weight and an additive effect on body fat (p<0.0001). Although ENT-03 animals lost more fat mass, lean mass loss was similar between the two groups (13%), reflecting greater % lean in ENT-03 (p<0.03). After discontinuation of treatment, weight gain occurred rapidly, with SG exceeding their initial starting weight, while ENT-03 treated mice maintained their weight and fat loss 10 wks after treatment discontinuation. After 10wks discontinuation, insulin levels remained lower in ENT-03, but not SG, treated mice. ENT-03 administration rapidly promoted lipid oxidation without evidence of increased energy expenditure. Conclusion: ENT-03 produces greater weight and fat loss than SG over 10 weeks of dosing, with relative preservation of lean mass and an additive effect on fat loss when used in combination with SG. Weight loss and lower insulin persist for at least 10 weeks after treatment with ENT-03 but not SG. W.A. Kinney: None. M.B. Zemel: Consultant; AdipoPharm, Aerami Therapeutics, Diasome Pharmaceuticals, Glyscend Therapeutics, Intercept Pharmaceuticals, Inc, NeuroBo Pharmaceuticals, Inc, Rhythm Pharmaceuticals, Inc, TIXiMED, Zealand Pharma A/S, Enterin. G. Fleming: Advisory Panel; Abvance Therapeutics. Consultant; AdipoPharm, ADOCIA, Aerami Therapeutics, Biocon. Stock/Shareholder; Diasome Pharmaceuticals. Consultant; Biomea Fusion, Glyscend Therapeutics, Intarcia Therapeutics, Inc, Kriya Therapeutics. Other Relationship; Juvenile Diabetes Research Foundation (JDRF). Consultant; Oramed Pharmaceuticals, Regor Therapeutics, Rhythm Pharmaceuticals, Inc, Rivus Pharmaceuticals Inc, TIXiMED, vTv Therapeutics, Zealand Pharma A/S, Zucara Therapeutics. A.C. Moses: Consultant; Vertex Pharmaceuticals Incorporated, Virta Health Corp, Alnylam Pharmaceuticals, Inc. Board Member; diaTribe. Stock/Shareholder; Minutia, Inc. Consultant; Scholar Rock. Advisory Panel; TIXiMED. R.S. Larson: Employee; Metabolics Pharma, Enterin Inc.

    2025Diabetes(2025)
    引用
    AI阅读
    加入学术空间
    4A First-in-class Series of Potent and Selective Macrocyclic ATR Inhibitors
    Molly M. Hansbarger, Stephen J. Rocca, Tina Gill, Hank Breslin, Lanqi Jia,Erin M. George, Inna Rom, Teresa Lee, Jonathan Weinstein,Fiona Simpkins,Eric J. Brown,Oren A. Gilad

    ATR, a phosphatidyl-inositol kinase-related kinase (PIKK), is a promising target for cancer treatment. Although ATR inhibitor (ATRi)-based therapies show increased activity in tumors that harbor various cancer-associated alterations, the therapeutic index of this drug class has remained a challenge. One potential risk factor in causing drug-related adverse is limited selectivity for the drug target (i.e. off-targeting). In small molecule drugs, macrocyclic structures can reduce the number of conformations possible and, thus, promote selectivity for their targets. Therefore, to increase the selectivity of ATRi and potentially reduce adverse effects of treatment, Aprea Therapeutics developed a first-in-class series of macrocyclic ATRi to potentially increase the tolerability of treatment while maintaining biomarker-driven efficacy. These macrocyclic ATRi are highly potent, with IC50s below 20 nM based on in vitro biochemical kinase assays and cellular inhibition of phosphorylation on S345 of CHK1, a direct ATR substrate. Notably, members of the Aprea series of macrocyclic ATRi demonstrate minimally off-target other PIKKs both in in vitro kinase assays and in cultured cells, with off-targeting of other PIKKs (ATM, PRKDC, MTOR, and SMG1) occurring at concentrations that are hundreds of fold greater than that required to inhibit ATR. Cell proliferation and replication fork stability assays confirm low nanomolar EC50s as single agents at levels that correlate with their ability to inhibit ATR. As expected based on ATR’s role in the replication stress and DNA damage responses, the antiproliferative effects of members of this macrocyclic ATRi series were amplified by co-treatment with DNA-damaging chemotherapies, such as topoisomerase inhibitors, PARP inhibitors, and platinum agents. Mouse xenograft tumor studies with one of the macrocyclic series members, ATRN-119, indicate single-agent activity in colon and prostate cancer models. Moreover, the growth of orthotopically transplanted BRCA2-deficient ovarian cancer PDX tumors is significantly impeded by ATRN-119 single agent treatment, and the combination of ATRN-119 with PARP inhibitor treatment in this model synergistically suppresses tumor growth and causes tumor regression. Overall, Aprea’s new class of macrocyclic ATRi represents a new class of ATRi with selectivity for inhibiting ATR over other PIKKs, has cellular activities that match biochemical and cellular inhibition of ATR, and exhibits tumor suppressive effects and a single agent and in combination with PARP inhibition. ATRN-119 is now progressing through Phase I clinical dose escalation studies. Molly M. Hansbarger, Stephen J. Rocca, Tina Gill, Hank Breslin, Lanqi Jia, Erin M. George, Inna Rom, Teresa Lee, Jonathan Weinstein, Fiona Simpkins, Eric J. Brown, Oren Gilad. A first-in-class series of potent and selective macrocyclic ATR inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2907.

    2025CANCER RESEARCH(2025)
    引用
    AI阅读
    加入学术空间
    5271-OR: Randomized Phase 1 Single-Ascending Dose Study of ENT-03 in Healthy Obese Subjects and Subjects with Type 2 Diabetes
    RICHARD S. LARSON, G. ALEXANDER FLEMING,MICHAEL B. ZEMEL,ALAN C. MOSES

    Introduction and Objective: Although GLP-1 agonists show efficacy treating obesity and T2D, significant side effects and high discontinuation rates occur. Drugs with different mechanisms of actions are needed for mono- and combination therapy. ENT-03 is a subcutaneously administered aminosterol antagonist of PTP1B that acts in the hypothalamus to decrease weight. Methods: This was a first-in-human, randomized, placebo-controlled Phase 1a study to evaluate the safety, tolerability, and pharmacokinetics and pharmacodynamic profile of single doses of ENT-03 from 3.0 mg to 75 mg in healthy obese subjects (BMI 30-35) and obese subjects with T2D (HbA1c 6.6%-8.5%). Although not powered for statistical significance, clinical efficacy was assessed with exploratory endpoints. Results: Forty-nine subjects were enrolled and randomized to either ENT-03 or placebo at a 5:2 (active: placebo) ratio. In healthy obese (n=27) and obese subjects with diabetes (n=8), ENT-03 was well-tolerated, with no safety signals, no treatment-emergent adverse events (TEAEs) ≥3, no SAEs and no TEAEs leading to study discontinuation. No vital sign, clinical lab or ECG changes were observed compared to baseline. All TEAEs were reported as mild (grade 1) or moderate (Grade 2), indicating a favorable AE profile. Mild nausea was observed in 4 patients, and 2 patients had moderate vomiting (3 mg dose and 50 mg dose). Four mild injection site reactions were observed and did not require intervention. t1/2 increased as doses increased in each treatment group with mean t1/2 of 72.3 hr (+7.1) at a dose of 75 mg. Of the 10 subjects receiving a single 50 mg dose, 8 lost an average of 0.99 kg on day 8 (p<0.04). All 8 subjects returned to baseline weight on day 14. In obese patients with type 2 diabetes, there was a trend toward decreased insulin, decreased Matsuda index, and decreased HOMA-IR. Conclusion: ENT-03 with a novel mechanism of action to treat obesity and/or T2D appears safe and well-tolerated in this Phase 1a study. R.S. Larson: Employee; Metabolics Pharma, Enterin Inc. G. Fleming: Advisory Panel; Abvance Therapeutics. Consultant; AdipoPharm, ADOCIA, Aerami Therapeutics, Biocon. Stock/Shareholder; Diasome Pharmaceuticals. Consultant; Biomea Fusion, Glyscend Therapeutics, Intarcia Therapeutics, Inc, Kriya Therapeutics. Other Relationship; Juvenile Diabetes Research Foundation (JDRF). Consultant; Oramed Pharmaceuticals, Regor Therapeutics, Rhythm Pharmaceuticals, Inc, Rivus Pharmaceuticals Inc, TIXiMED, vTv Therapeutics, Zealand Pharma A/S, Zucara Therapeutics. M.B. Zemel: Consultant; AdipoPharm, Aerami Therapeutics, Diasome Pharmaceuticals, Glyscend Therapeutics, Intercept Pharmaceuticals, Inc, NeuroBo Pharmaceuticals, Inc, Rhythm Pharmaceuticals, Inc, TIXiMED, Zealand Pharma A/S, Enterin. A.C. Moses: Consultant; Vertex Pharmaceuticals Incorporated, Virta Health Corp, Alnylam Pharmaceuticals, Inc. Board Member; diaTribe. Stock/Shareholder; Minutia, Inc. Consultant; Scholar Rock. Advisory Panel; TIXiMED.

    2025Diabetes(2025)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 99 篇论文

    合作机构(100)

    威廉·比蒙医院合作论文 6
    杜克大学合作论文 5
    温纳贝戈医学中心合作论文 4
    加州大学旧金山分校合作论文 3
    贝斯以色列女执事医疗中心合作论文 3
    哥伦比亚大学合作论文 3
    科罗拉多州立大学合作论文 2
    Texas Cardiac Arrhythmia合作论文 2
    密歇根大学合作论文 2
    托马斯杰斐逊大学合作论文 2

    机构统计